Using fixed-dose combination therapies to achieve blood pressure goals

Clinical Drug Investigation

Volumn 28, Issue 11, 2008, Pages 713-734

  Chrysant, Steven G ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Oklahoma Cardiovascular and Hypertension Center   (United States)

Author keywords

ACE inhibitors, therapeutic use; Alpha 2 adrenergic receptor antagonists, therapeutic use; Amlodipine benazepril, therapeutic use; Amlodipine valsartan, therapeutic use; Angiotensin II 1 receptor antagonists, therapeutic use

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL PLUS CHLORTALIDONE; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPROSARTAN; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; MOEXIPRIL; OLMESARTAN; TIMOLOL; UNINDEXED DRUG;

BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 53549086415     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828110-00005     Document Type: Review

References (104)

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49 (1): 69-75
2. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328 (13): 914-21
3. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72
5. Chrysant SG. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998; 7 (4): 370-6
6. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87
7. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713-9
8. Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993; 15 (6): 1299-313
9. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156 (17): 1969-78
10. Frishman WH. Results of hypertension treatment with low-dose combinations of a beta-adrenergic blocker and a diuretic. Am J Hypertens 1997; 10 (3): 17S-23S
11. Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992; 6 Suppl. 2: S19-21
12. Neutel JM, Black HR, Weber MA. Combination therapy with diuretics: an evolution of understanding. Am J Med 1996; 101 (3A): 61S-70S
13. Bonner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004; 20 (5): 597-602
14. Campo C, Fernandez G, Gonzalez-Esteban J, et al. Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. Blood Press 2000; 9 (6): 355-62
15. Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007; 9 (1): 36-44
16. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17 (6): 495-501
17. Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40mg telmisartan plus 12.5mg hydrochlorothiazide with 40mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002; 9 (2): 111-7
18. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA 2003; 290 (21): 2805-16
19. Ruilope LM, de la Sierra A, Moreno E, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy: a randomized trial. The EDICTA study. J Hypertens 1999; 17 (12 Pt 2): 1917-23
20. Ram CV. Antihypertensive drugs: an overview. Am J Cardiovasc Drugs 2002; 2 (2): 77-89
21. Chrysant SG, Fagan T, Glazer R, et al. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 1996; 5 (1): 17-24
22. Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol 1987; 23 Suppl. 1: 43-50S
23. Brown CL, Backhouse CI, Grippat JC, et al. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990; 39 (4): 327-32
24. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med 1994; 154 (7): 737-43
25. Holland OB, von Kuhnert L, Campbell WB, et al. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension 1983; 5 (2): 235-9
26. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122 (2): 133-41
27. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: S36-42
28. Guul SJ, Os I, Jounela AJ. The efficacy and tolerability of enalapril in a formulation with a very low dose of hydrochlorothiazide in hypertensive patients resistant to enalapril monotherapy. Am J Hypertens 1995; 8 (7): 727-31
29. Middlemost SJ, Tager R, Davis J, et al. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 1994; 73 (15): 1092-7
30. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150 (6): 1175-83
31. Ratheiser K, Dusleag J, Seitl K, et al. A 'lipo-protective' effect of a fixed combination of captopril and hydrochlorothiazide in antihypertensive therapy. Clin Cardiol 1992; 15 (9): 647-54
32. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension. A clinical trial of factorial design. The East Germany Collaborative Trial Group. J Hypertens 1993; 11 (2): 217-21
33. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996; 28 (2): 269-75
34. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998; 135 (2 Pt 2): S21-30
35. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334 (15): 939-45
36. Sihm I, Schroeder AP, Aalkjaer C, et al. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Am J Cardiol 1995; 76 (15): 38-40E
37. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45 (2): 205-51
38. Chrysant SG, Chrysant GS. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich) 2004; 6 (8): 445-51
39. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-9
40. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23 (6): 833-50
41. Ruilope LM, Simpson RL, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5 (1): 32-40
42. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6 (10): 569-77
43. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12 (12): 861-6
44. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12 (8 Pt 1): 797-805
45. Chrysant SG, Chappel C, Farnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992; 32 (1): 61-5
46. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154 (13): 1461-8
47. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35 (2): 182-8
48. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163 (5): 525-41
49. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17 (7): 590-6
50. Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press 2007; 1 Suppl.: 10-7
51. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension: Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79 (4): 431-5
52. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
53. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366 (9489): 869-71
54. Jamerson KA, Weber MA, Bakris GL, et al. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension, the early termination of the ACCOMPLISH trial for efficacy [abstract no. 407-7]. 57th Annual Scientific Session of the American College of Cardiology: 2008 Mar 31, Chicago (IL)
55. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29 (4): 563-80
56. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30 (4): 587-604
57. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31
58. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345-53; discussion 54-6
59. See S. Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother 2001; 2 (11): 1795-804
60. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24 (7): 1405-12
61. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005; 19 (12): 923-31
62. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 2004; 40 (9): 791-801
63. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547-59
64. Whitsett TL, Chrysant SG, Dillard BL, et al. Abrupt cessation of clonidine administration: a prospective study. Am J Cardiol 1978; 41 (7): 1285-90
65. Amery A, Verstraete M, Bossaert H, et al. Hypotensive action and side effects of clonidine-chlorthalidone and methyldopachlorthalidone in treatment of hypertension. BMJ 1970; 4 (5732): 392-5
66. Gray DR, Weber MA, Drayer JI. Effects of low-dose antihypertensive therapy in elderly patients with predominant systolic hypertension. J Gerontol 1983; 38 (3): 302-6
67. Noveck RJ, McMahon FG, Jain AK, et al. Clonidine-chlorthalidone combination once and twice daily in essential hypertension. Clin Pharmacol Ther 1980; 28 (5): 581-6
68. Thananopavarn C, Golub MS, Sambhi MP. Clonidine in the elderly hypertensive: monotherapy and therapy with a diuretic. Chest 1983; 83 (2 Suppl.): 410-1
69. Weber MA, Drayer JI, Gray DR. Combined diuretic and sympatholytic therapy in elderly patients with predominant systolic hypertension. Chest 1983; 83 (2 Suppl.): 416-8
70. Reisin E, Weed SG. The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine. J Hypertens 1992; 10 (5): 489-93
71. Graham RD. Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. J Hum Hypertens 1991; 5 Suppl. 2: 59-60
72. Sapienza S, Sacco P, Floyd K, et al. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther 2003; 25 (6): 1872-87
73. Schweizer J, Hilsmann U, Neumann G, et al. Efficacy and safety of valsartan 160/HCTZ 25mg in fixed combination in hypertensive patients not controlled by candesartan 32mg plus HCTZ 25mg in free combination. Curr Med Res Opin 2007; 23 (11): 2877-85
74. Cremonesi G, Cavalieri L, Cikes I, et al. Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. Adv Ther 2002; 19 (3): 129-37
75. Luccioni R, Sever PS, Di Perri T, et al. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995; 13 (12 Pt 2): 1847-51
76. Rosei EA, Rizzoni D. Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. J Hum Hypertens 2003; 17 (2): 139-46
77. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18 (11): 1482-8
78. Fuenfstueck R, Hempel RD, Ansari A, et al. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers. Adv Ther 2005; 22 (3): 263-77
79. Lacourciere Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57 (4): 273-9
80. Lacourciere Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5mg and 80/12.5mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005; 27 (11): 1795-805
81. Neutel JM, Littlejohn TW, Chrysant SG, et al. Telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005; 28 (7): 555-63
82. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/ hydrochlorothiazide and losartan/hydrochlorothiahyzide in patients with mild-to-moderate hypertension. J Int Med Res 2005; 33 (6): 620-31
83. Leikersfeldt G, Rasmussen SL, Atmer B, et al. Efficacy and tolerability of a fixed combination of metoprolol CR/ZOK 100mg and hydrochlorothiazide (HCT) 12.5mg in comparison with the fixed combination of metoprolol and HCT. J Clin Pharmacol 1990; 30 (2 Suppl.): S78-81
84. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29 (12): 2592-7
85. Breithaupt-Grögler K, Gerhardt G, Lehmann G, et al. Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther 1998; 36 (8): 425-31
86. Cifková R, Nakov R, Novozámská E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 2000; 14 (6): 347-54
87. De la Sierra A, Gil-Extremera B, Calvo C, et al. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens 2004; 18 (3): 215-22
88. De Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. J Hypertens 1997; 15 (1): 87-91
89. Holzgreve H, Nakov R, Beck K, et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003; 16 (5 Pt 1): 381-6
90. Maharaj B, van der Byl K. Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlorthalidone and atenolol in the treatment of mild to moderate hypertension in black patients. J Hum Hypertens 1993; 7 (5): 447-50
91. Malacco E, Piazza S, Carretta R, et al. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int J Clin Pharmacol Ther 2002; 40 (6): 263-9
92. Middeke M, Richter WO, Schwandt P, et al. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther 1997; 35 (6): 231-4
93. Mugellini A, Dobovisek J, Planinc D, et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004; 26 (9): 1419-26
94. US Department of Health and Human Services. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; 1998. Report No.: Clinical 6
95. ICH Steering Committee. Guidance document: principles for evaluation of new antihypertensive drugs [online]. Available from URL: www.http://www.fda.gov/ cder/Guidance/3774dft.htm [Accessed 2008 Oct 2]
96. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326 (7404): 1427
97. Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005; 18 (7): 935-42
98. Borghi C, Dormi A, D'Addato S, et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22 (9): 1707-16
99. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117 (6): 743-53
100. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 1971; 27 (4): 335-46
101. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36 (4): 594-9
102. Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich) 2006; 8 (12): 865-72
103. Ferrari P, Hess L, Pechere-Bertschi A, et al. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens 2004; 22 (6): 1221-9
104. Sica DA. Fixed-dose combination antihypertensive drugs: do they have a role in rational therapy? Drugs 1994; 48 (1): 16-24